Trading Information Summary - On February 2, ST Tianrui (300165) closed at 4.94 yuan, down 1.4%, with a turnover rate of 1.38% and a trading volume of 58,100 hands, amounting to 29.05 million yuan [1] - On the same day, the net inflow of main funds was 181,800 yuan, while retail funds saw a net inflow of 118,000 yuan, indicating a slight advantage for the market's bullish forces [2] Company Announcement Summary - ST Tianrui has received the formal administrative penalty decision from the China Securities Regulatory Commission (CSRC) and has completed the correction of accounting errors in the 2021 annual report. The company plans to apply for the cancellation of the risk warning after the rectification is completed [1][2] - The company’s stock will be subject to other risk warnings starting from December 10, 2024, due to the receipt of the CSRC's administrative penalty notice [1]

证券代码：300165 证券简称：ST天瑞 公告编号：2026-004 江苏天瑞仪器股份有限公司 一、实施其他风险警示的原因 公司于2024年12月6日收到中国证监会出具的《行政处罚事先告知书》，根据 《行政处罚事先告知书》认定的情况，公司涉及的违法违规行为触及《深圳证券 交易所创业板股票上市规则》第9.4条第（七）项规定的被实施其他风险警示情形， 公司股票于2024年12月10日起被实施其他风险警示，具体内容详见公司在巨潮资 讯网上披露的《关于公司股票交易被实施其他风险警示暨股票停复牌的提示性公 告》（公告编号：2024-074）。 二、采取的措施及进展情况 1、针对《行政处罚决定书》所涉事项，公司于2024年4月24日召开了第六 届董事会第七次会议和第六届监事会第五次会议，审议通过了《关于前期会计 差错更正及追溯调整的议案》，对2021年年报进行了会计差错更正及追溯调整， 并于2024年4月26日披露了《关于公司前期会计差错更正及追溯调整的公告》 （公告编号：2024-015）等相关文件。目前，公司不存在尚未整改完毕的事项。 关于公司股票被实施其他风险警示相关事项的进展公告 本公司及董事会全体成员保证信息 ...

Core Viewpoint - ST Tianrui (300165.SZ) expects a net profit attributable to shareholders of the listed company to be between -240 million and -170 million yuan for 2025, with a net profit after deducting non-recurring gains and losses estimated at -246.51 million to -176.51 million yuan [1] Financial Performance - The company anticipates a significant net loss for 2025, indicating ongoing financial challenges [1] - The projected net loss reflects a deterioration in market conditions affecting the company's operations [1] Project Status - The company's subsidiary, Qingshui Jingsheng Living Waste Resource Utilization Co., Ltd., has halted its PPP project due to changes in market conditions and plans to pursue external transfer of the project [1] - In accordance with the relevant provisions of the Accounting Standards for Enterprises No. 8 on asset impairment, the company plans to make an asset impairment provision of 85 million to 100 million yuan for the related contract assets of the project [1]

证券代码：300165 证券简称：ST天瑞 公告编号：2026-003 江苏天瑞仪器股份有限公司 关于控股股东收到仲裁裁决书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，江苏天瑞仪器股份有限公司（以下简称"公司"或"天瑞仪器"）收 到公司控股股东刘召贵先生提交的上海国际经济贸易仲裁委员会（上海国际仲裁 中心）出具的《裁决书》（上国仲（2025）第 1729 号），上海国际经济贸易仲 裁委员会（上海国际仲裁中心）就刘召贵先生与广州立多虚拟现实科技合伙企业 (有限合伙)(以下简称"立多虚拟")之间股份转让协议纠纷事项做出终局裁决， 现将相关情况公告如下： 一、情况概述 2023 年 5 月 12 日，刘召贵先生与立多虚拟签订《刘召贵与广州立多虚拟现 实科技合伙企业(有限合伙)关于江苏天瑞仪器股份有限公司之股份转让协议》， 约定将其名下 5.01%的天瑞仪器股份以 4.7 元/股的价格转让给立多虚拟，合同总 价款为 116,678,143.90 元。 2023 年 5 月 19 日，立多虚拟按照合同约定向刘召贵先生支付了第一笔转让 款，即合同总价款的 ...

Financial Performance Expectations - The company expects a net profit in the range of -24,000 to -17,000 thousand yuan for the fiscal year 2025, representing a decline of 146.61% to 74.68% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be between -24,651 and -17,651 thousand yuan, reflecting a decrease of 148.20% to 77.72% year-over-year[3] Asset Impairment Provisions - The company plans to recognize an asset impairment provision of 85,000 to 100,000 thousand yuan related to the PPP project of its subsidiary, which is currently stagnant and intended for external transfer[4] - An inventory impairment provision of 35,000 to 40,000 thousand yuan is expected to be recognized based on the company's accounting policies and prudence principle[4] - The company anticipates goodwill impairment of approximately 35,000 to 41,800 thousand yuan for its subsidiaries, based on their business composition and future expectations[4] Investor Guidance - The financial data for the fiscal year 2025 will be detailed in the company's annual report, urging investors to make cautious decisions and be aware of investment risks[5]

证券代码：300165 证券简称：ST天瑞 公告编号：2026-001 江苏天瑞仪器股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、实施其他风险警示的原因 公司于2024年12月6日收到中国证监会出具的《行政处罚事先告知书》，根据 《行政处罚事先告知书》认定的情况，公司涉及的违法违规行为触及《深圳证券 交易所创业板股票上市规则》第9.4条第（七）项规定的被实施其他风险警示情形， 公司股票于2024年12月10日起被实施其他风险警示，具体内容详见公司在巨潮资 讯网上披露的《关于公司股票交易被实施其他风险警示暨股票停复牌的提示性公 告》（公告编号：2024-074）。 二、采取的措施及进展情况 1、针对《行政处罚决定书》所涉事项，公司于2024年4月24日召开了第六 届董事会第七次会议和第六届监事会第五次会议，审议通过了《关于前期会计 差错更正及追溯调整的议案》，对2021年年报进行了会计差错更正及追溯调整， 并于2024年4月26日披露了《关于公司前期会计差错更正及追溯调整的公告》 ...

Core Viewpoint - ST Tianrui has resumed trading after terminating the planned change of control, with the stock closing at 4.60 yuan, reflecting a decline of 0.86% and a total market capitalization of 2.279 billion yuan [1]. Group 1 - The company announced the termination of the planned change of control due to a lack of consensus between the controlling shareholder and the counterparties involved [1]. - The decision to terminate the control change was made in a cautious manner, ensuring that it would not have a significant adverse impact on the company's operational performance and financial status [1]. - The company’s operations remain normal despite the termination of the control change plan [1]. Group 2 - The company applied to the Shenzhen Stock Exchange for the resumption of trading, which took effect on December 8, 2025 [2].

Core Viewpoint - The establishment of the Analysis Instrument Professional Committee under the China Nuclear Instrument Association marks a significant step towards integrating industry resources, promoting collaborative innovation, and strengthening standard leadership in the nuclear instrument sector [2][8][25]. Group 1: Event Overview - The founding conference of the Analysis Instrument Professional Committee took place on December 5, 2025, in Beijing, attended by industry professionals and experts [2][5]. - The meeting was hosted by Ma Jing, Chief Expert of China National Nuclear Corporation, with notable attendees including leaders from the National Defense Science and Technology Industry Bureau and the China Nuclear Instrument Association [2][8]. Group 2: Leadership and Structure - The conference included the election of the first council members, with Hou Liudong elected as the chairman and several vice-chairmen and directors appointed [13]. - The establishment of the committee was officially recognized with a plaque presentation by Xu Pengfei, representing the China Nuclear Instrument Association [13][25]. Group 3: Strategic Importance - The committee aims to address the increasing demands for precision, reliability, intelligence, and localization in analysis instruments due to the deepening application of nuclear technology across various sectors [25]. - There is a pressing need for breakthroughs in key technologies, construction of standard systems, and deep integration of production, learning, research, and application to enhance the overall capabilities of the industry and ensure the security of the industrial chain [25]. Group 4: Academic Contributions - The conference featured high-level reports from renowned experts in the field, covering topics such as single-cell immune mass spectrometry and key technologies for digitalization of material properties [20][21]. - These discussions provided significant academic insights and shared cutting-edge technologies relevant to the analysis instrument sector [20].

Group 1 - Century Huatong plans to change the use of 1.28 million repurchased shares from equity incentive plans to cancellation, reducing total share capital from 7.428 billion to 7.427 billion shares [2] - Wuliangye adjusts its 2025 investment plan, increasing the number of projects from 19 to 22 and changing the investment amount from 2.586 billion to 2.207 billion yuan [3] - Qingyue Technology is under investigation for suspected financial data fraud, with the possibility of forced delisting if found guilty [4] Group 2 - Kang Enbei's chairman and legal representative resigns due to work adjustments, along with another board member [5] - Tianshan Co. expects a tax payment of approximately 61.86 million yuan to impact its 2025 net profit [6] - Muyuan Foods reports a 20.43% year-on-year decline in November sales revenue from live pigs, totaling 9.39 billion yuan [7] Group 3 - GAC Group's November automobile sales decreased by 9.72% year-on-year, with total sales of 1.797 million vehicles [8] - Western Pastoral's fresh milk production in November increased by 6.3% month-on-month but decreased by 6.47% year-on-year [9] - Gemdale Group's November contracted area fell by 58.50% year-on-year, with a total contracted amount of 1.52 billion yuan [10] Group 4 - Zhenghong Technology reports November sales revenue of 4.5196 million yuan from live pigs, with a year-on-year decline of 21.83% [11] - Wens Foodstuff's November chicken sales reached 118 million birds, generating 3.324 billion yuan in revenue [12] - Meilixin's controlling shareholder plans to increase holdings by no less than 50 million yuan [13] Group 5 - Hongcheng Environment's subsidiary wins an 853 million yuan sewage treatment project [14] - Dongzhu Ecology wins a 397 million yuan environmental project [15] - Xindian Software secures a 54 million yuan project for digital community construction [16] Group 6 - China Chemical announces that its nylon new material project has reached full production [17] - Jiaojian Co. is in discussions regarding overdue payments related to financial products, clarifying that it bears no responsibility for these products [18] - Micron Biotech's product is included in the 2025 National Medical Insurance Directory [19] Group 7 - Yitian Intelligent plans to sell 600 smart computing machines for a total of 1.56 billion yuan [20] - First Venture's subsidiary receives an administrative penalty notice from Jiangsu Securities Regulatory Bureau [21] - China Insurance's vice president is under investigation for serious violations [22] Group 8 - Zhixiang Jintai's monoclonal antibody injection is included in the 2025 National Medical Insurance Directory [23] - Haichuang Pharmaceutical's drug is also included in the National Medical Insurance Directory [24] - Yuanli Co. plans to acquire 49% of Clarimex for 25.56 million USD [25] Group 9 - Betta Pharmaceuticals' products are included in the National Medical Insurance Directory [26] - Tianci Materials' controlling shareholder commits to not reducing holdings for six months [27] - Guanglian Aviation's actual controller has had a detention measure lifted [28] Group 10 - Annie Co. announces a share transfer agreement that will make Shengshi Tianan the controlling shareholder [29] - Double Star New Materials notes uncertainty regarding the sustainability of long-term price increases [30] - ST Tianrui terminates plans for a change in control and resumes trading [31] Group 11 - Guao Technology is planning a change in control, leading to a temporary suspension of its stock [32] - Guangqi Technology's subsidiary signs contracts worth 696 million yuan for the production of metamaterials [33] - Shuoshi Biotech's monkeypox virus detection kit is included in the WHO emergency use list [34]

Core Viewpoint - Jiangsu Tianrui Instrument Co., Ltd. has terminated the planning of a change in company control, which will not adversely affect its operations or future development strategy [2][3]. Group 1: Suspension of Trading - The company's stock (ST Tianrui, stock code: 300165) was suspended from trading starting December 1, 2025, due to the potential change in control involving the controlling shareholder and actual controller Liu Zhaogui [2]. - The suspension was implemented to ensure fair information disclosure and prevent abnormal fluctuations in the stock price during the planning phase of the control change [2]. Group 2: Termination of Control Change Planning - The termination of the control change planning was due to the lack of consensus on significant matters between the controlling shareholder and the transaction counterpart [3]. - The company confirmed that its operational status remains normal and that the termination will not have a significant adverse impact on its financial performance [3]. Group 3: Resumption of Trading - The company's stock is set to resume trading on December 8, 2025, following the termination of the control change planning [4]. - The company has expressed apologies for any inconvenience caused to investors due to the termination of the control change planning [4].